

Date: March 31, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Subject : Disclosure under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Reference: Supriya Lifescience Limited Scrip Code: 543434

Dear Sir/Madam,

With reference to the above captioned matter, please find enclosed herewith, disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the acquisition made on March 29, 2023.

You are requested to take the same on your records.

Thanking You,

Yours Faithfully,

Dr. Satish Wagh

cc to :
The Company Secretary and Compliance Officer
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon (East),
Mumbai – 400063.

ANNEXURE - 1

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Supriya Lifescience Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Dr. Satish Wagh		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange of India Ltd. 2. BSE Ltd.		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	54414205	67.609	67.609
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)			

<p>Details of acquisition/sale</p> <p>a) Shares carrying voting rights acquired/sold</p> <p>b) VRs acquired/sold otherwise than by equity shares</p> <p>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold</p> <p>d) Shares encumbered / invoked/released by the acquirer</p> <p>e) Total (a+b+c+/-d)</p>	14,000	0.017	0.017
<p>After the acquisition/sale, holding of :</p> <p>a) Shares carrying voting rights</p> <p>b) Shares encumbered with the acquirer</p> <p>c) VRs otherwise than by shares</p> <p>d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition</p> <p>e) Total (a+b+c+d)</p>	54428205	67.627	67.627
<p>Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue preferential allotment / inter-se transfer etc).</p>	Open Market		
<p>Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable</p>	29.03.2023		

Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)
Total diluted share/voting capital of the TC after the said acquisition	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Dr. Satish Wagh

Place: Mumbai

Date: 31.03.2023